20662-52-6

Usage

Uses

Used in Pharmaceutical Industry:
4,4-Bis(4-fluorophenyl)butyric acid is used as a precursor in the synthesis of various drugs, particularly nonsteroidal anti-inflammatory drugs (NSAIDs). Its unique structure allows for the development of new and effective medications to treat inflammation and pain.
Used in Neurological Disorders Research:
In the field of neurological disorders, 4,4-Bis(4-fluorophenyl)butyric acid is being studied for its potential use in the treatment of Alzheimer's disease and schizophrenia. It modulates the gamma-aminobutyric acid (GABA) neurotransmitter system, which plays a crucial role in regulating neuronal excitability and is implicated in the pathophysiology of these disorders.
Used in Cancer Research:
4,4-Bis(4-fluorophenyl)butyric acid has shown promise in research as a potential therapeutic agent for the treatment of cancer. Its ability to modulate various cellular pathways and target specific cancer cells makes it a valuable compound for further investigation in oncology.
Used in Inflammatory Conditions Research:
In addition to its potential use in cancer treatment, FFB is also being studied for its potential in treating inflammatory conditions. Its anti-inflammatory properties could be harnessed to develop new treatments for a range of inflammatory diseases, improving patient outcomes and quality of life.

InChI:InChI=1/C16H14F2O2/c17-13-5-1-11(2-6-13)15(9-10-16(19)20)12-3-7-14(18)8-4-12/h1-8,15H,9-10H2,(H,19,20)

Upstream product

• 462-06-6 fluorobenzene 
• 51787-96-3 5-(4-fluorophenyl)dihydrofuran-2(3H)-one 
• 337506-83-9 1,1-bis(4-fluorophenyl)butane-1,4-diol 
• 352-13-6 4-flourophenylmagnesium bromide 
• 366-77-8 4-(4-fluorophenyl)-4-oxopropionic acid 
• 50337-85-4 4,4-bis(4-fluorophenyl)butan-1-ol 

Downstream Products

• 1266656-43-2 8-(4,4-bis(4-fluorophenyl)butanoyl)-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one 
• 26864-56-2 penfluridol 
• 50830-38-1 1-[4,4-bis(4-fluorophenyl)butyryl]-4-(3-trifluoromethyl-4-chlorophenyl)-4-piperidinol 
• 57668-61-8 4,4'-(4-bromobutane-1,1-diyl)bis(fluorobenzene) 
• 68351-25-7 6-Fluor-1-(4-fluor-phenyl)-1,2-dihydro-naphthalin 
• 808749-38-4 (1-{1-[4,4-bis(4-fluorophenyl)butyryl]piperidin-4-ylcarbamoyl}-3-methylbutyl)carbamic acid tert-butyl ester 
• 808749-39-5 (1-{1-[4,4-bis(4-fluorophenyl)butyryl]piperidin-4-ylcarbamoyl}-3-methylbutyl)methylcarbamic acid tert-butyl ester 
• 808749-29-3 4,4-bis(4-fluorophenyl)-N-(piperidin-4-yl)butyramide 
• 808749-34-0 1-(4-aminopiperidin-1-yl)-4,4-bis(4-fluorophenyl)butan-1-one 
• 1002750-52-8 1-(4,4-dihydroxypiperidin-1-yl)-4,4-bis-(4-fluorophenyl)butan-1-one 
• 808749-33-9 (1-[4,4-bis(4-fluorophenyl)butyryl]piperidin-4-yl)carbamic acid tert-butyl ester 
• 808749-28-2 N-(1-benzylpiperidin-4-yl)-4,4-bis(4-fluorophenyl)butyramide 
• 68351-21-3 7-Fluoro-4-(4-fluorophenyl)-1,2,3,4-tetrahydronaphthalene-1-one 
• 50337-85-4 4,4-bis(4-fluorophenyl)butan-1-ol 

Relevant academic research and scientific papers

Fluspirilene Analogs Activate the 20S Proteasome and Overcome Proteasome Impairment by Intrinsically Disordered Protein Oligomers

Oligomerization of aggregation-prone intrinsically disordered proteins (IDPs), such as α-synuclein, amyloid β, and tau, has been shown to be associated with the pathogenesis of several neurodegenerative diseases, including Parkinson's and Alzheimer's disease. The proteasome is charged with regulating cellular levels of IDPs, but this degradation pathway can become dysregulated leading to their accumulation and subsequent aggregation. Although the pathogenesis of these neurodegenerative diseases is still under intense investigation, it has been shown that the oligomeric forms of IDPs, including α-synuclein and amyloid β, can impair proteasome function. This leads to additional accumulation of the IDPs, further promoting disease progression. Herein, we report the use of small molecule activators of the 20S subcomplex of the proteasome to restore impaired 20S proteasome activity and prevent IDP accumulation and oligomerization. We found that fluspirilene and its new synthetic analog (16) show strong 20S proteasome enhancement (doubling 20S proteolytic activity at μ2 μM, with maximum fold enhancement of μ1000%), overcome impaired proteasome function, and prevent the accumulation of pathogenic IDPs. These findings provide support for the use of 20S enhancers as a possible therapeutic strategy to combat neurodegenerative diseases.

Penfluridol preparation method

The invention discloses a penfluridol preparation method. The penfluridol preparation method includes the following steps of 1), subjecting succinic anhydride and fluorobenzene to Friedel-Crafts reaction prior to acid decomposition, and collecting a compound from the formula 2) as is shown in the description; 2), putting the compound in a solvent to collect a compound in formula 3) as is shown in the description in a solvent reduced through a reducing agent; 3), putting the compound into the fluorobenzene to perform the Friedel-Crafts reaction to collect a compound in the formula 4) as is shown in the description; subjecting the compound and ethyl chloroformate to action to generate a compound in formula 5) as is shown in the description; 5), subjecting the compound and a compound shown in formula (XVII) to reaction prior to hydrolyzation to collect a compound in formula 6) as is shown in the description; 6), performing reduction with the reducing agent prior to hydrolyzing a reduction product and then collecting penfluridol (I). The penfluridol preparation method is high in yield, low in cost, moderate in reaction condition, short in circuit, proper for industrial production, low in three wastes, easy to treat and suitable for industrial production.

Synthesis and SAR study of diphenylbutylpiperidines as cell autophagy inducers

A novel series of diphenylbutylpiperidines as autophagy inducers was described and extensive SAR studies resulted in derivatives (15d-e, 15i-j) with 10-fold greater activity than the lead compounds 1 and 2. Meanwhile, a new synthetic route to diphenylbutyl bromide (6) from bromobenzene and γ-butyrolactone was also reported here.